Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Eli Lilly and Company
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Strong business, valuation above the sector
Get notified when we ship meaningful updates. No spam, no daily noise.
2 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Stable quality
Profitability
3/4
Debt & liquidity
2/3
Efficiency
2/2
Revenue grew 44.7% year over year — +663% above the sector median of 5.9% — and EPS growth of 96.0% ran +1,211% above the median 7.3%, a combination that places Eli Lilly and Company in the top quartile of Health Care on both measures. ROE of 101.2% sits +280% above the sector median 26.6%, and the F-Score of 7/9 reflects a balance sheet that is holding its shape. The price paid for that quality is steep: EV/EBITDA of 72.9× runs +226% above the sector median 22.3×, and P/B of 44.6× exceeds the median 6.4× by +599%. Consensus and the realized track record are aligned here — the forward PEG reads as fair and the three-year EPS CAGR in SEC filings supports what analysts model — yet the multiples leave little room for a growth shortfall.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is steady; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
When Lilly reports on October 29, 2026, track revenue growth year over year against the current 5.86% sector median — LLY ran 7.6× above that figure last period. Also check whether the F-Score profitability pillar holds its 3/4 reading, particularly the return-on-assets signal.
In the annual report's Management Discussion section, look for disclosures on GLP-1 manufacturing capacity and pricing pressure — both bear directly on sustaining the 26.6% ROE that sits 3.8× above the sector median. The risk factors section will also clarify pipeline concentration exposure.
Pick two or three names from the alphabetical Health Care table in section 06 and line up EV/EBITDA: LLY currently sits at 22.3×, roughly 3.3× the sector median. That spread is the core tension in the archetype — strong earnings growth paired with a valuation that leaves little room for execution misses.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: 1.944.323.242.43
Over 4 years: +1%+20%+32%+45%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 6 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 6/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly and Company | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.